Phase 2 Study to Assess the Safety and Efficacy of ANG003 (NCT07450547)
A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
🩺 Plain-English Summary (8th-Grade Level)
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Who can join: Review the eligibility criteria below.
Location: Long Beach Memorial Medical Center — Long Beach, California
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Long Beach Memorial Medical Center — Long Beach, California
- Center for Cystic Fibrosis at Keck Medical Center of USC — Los Angeles, California
- National Jewish Health — Denver, Colorado
- University of Florida — Gainesville, Florida
- Central Florida Pulmonary Group — Orlando, Florida
- The Cystic Fibrosis Institute — Glenview, Illinois
- University of Iowa — Iowa City, Iowa
- University of Kansas Medical Center — Kansas City, Kansas
- University of Kentucky — Lexington, Kentucky
- MaineHealth Pediatric Specialty Care — Portland, Maine
- Massachusetts General Hospital — Boston, Massachusetts
- Boston Children's Hospita — Boston, Massachusetts
- University of Michigan, Michigan Medicine — Ann Arbor, Michigan
- Wayne State University Harper University Hospital — Detroit, Michigan
- Rutgers - Robert Wood Johnson Medical School — New Brunswick, New Jersey
- New York Medical College at Westchester Medical Center — Valhalla, New York
- Children's Hospital Medical Center of Akron — Akron, Ohio
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Nationwide Children's Hospital, Columbus — Columbus, Ohio
- Toledo Children's Hospital — Toledo, Ohio
- Hershey Medical Center Pennsylvania State University — Hershey, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- University of Texas Southwestern / Children's Health — Dallas, Texas
- Adult Cystic Fibrosis Center at the University of Utah — Salt Lake City, Utah
- University of Wisconsin — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (617) 466-3111
Email: medical@anagramtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Exocrine Pancreatic Insufficiency (EPI)
Explore by condition: All Exocrine Pancreatic Insufficiency (EPI) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.